Background: Previous studies have shown various positive associations between the usual source of care (USC) and medication adherence in chronic diseases. However, no studies specifically on patients with diabetes have been conducted in Korea. This study examined the association between the USC type and medication adherence in patients with diabetes. Methods: Data from the 2021 Korea Health Panel Survey were used. The final sample comprised 1,493 participants aged ≥20 years. The types of USC were categorized into three groups: no USC, place only (without a regular doctor [RD]), and RD. Medication adherence was assessed using detailed items (dose, frequency, time, and discontinuation) and a four-point Likert scale. Logistic regression analysis was conducted with adjustment for control variables. Results: The odds ratios (ORs) for overall medication adherence were significantly higher in the RD group at 1.66 (95% confidence interval [CI], 1.15– 2.40) than in the no-USC group. No significant difference was observed in the place-only group at 0.73 (95% CI, 0.49–1.09). The ORs for medication adherence for each item (dosage, frequency, and timing) were also significantly higher in the RD group (2.21, 1.95, and 1.67, respectively). No statistically significant differences in these parameters were observed in the place-only group. Conclusion The presence of an RD positively affected medication adherence in patients with diabetes, but the presence of place-only did not. These findings emphasize the importance of an RD for medication adherence.

Cynaropicrin, a sesquiterpene lactone found in artichoke leaves exerts diverse pharmacological effects. This study investigated whether cynaropicrin has a paraptosis-like cell death effect in human hepatocellular carcinoma Hep3B cells in addition to the apoptotic effects reported in several cancer cell lines. Cynaropicrin-induced cytotoxicity and cytoplasmic vacuolation, a key characteristic of paraptosis, were not ameliorated by inhibitors of necroptosis, autophagy, or pan caspase inhibitors in Hep3B cells. Our study showed that cynaropicrin-induced cytotoxicity was accompanied by mitochondrial dysfunction and endoplasmic reticulum stress along with increased cellular calcium ion levels. These effects were significantly mitigated by endoplasmic reticulum stress inhibitor or protein synthesis inhibitor. Moreover, cynaropicrin treatment in Hep3B cells increased reactive oxygen species generation and downregulated apoptosis-linked gene 2-interacting protein X (Alix), a protein that inhibits paraptosis. The addition of the reactive oxygen species scavenger N-acetyl-L-cysteine (NAC) neutralized cynaropicrin-induced changes in Alix expression and endoplasmic reticulum stress marker proteins counteracting endoplasmic reticulum stress and mitochondrial impairment. This demonstrates a close relationship between endoplasmic reticulum stress and reactive oxygen species generation. Additionally, cynaropicrin activated p38 mitogen activated protein kinase and a selective p38 mitogen activated protein kinase blocker alleviated the biological phenomena induced by cynaropicrin. NAC pretreatment showed the best reversal of cynaropicrin induced vacuolation and cellular inactivity. Our findings suggest that cynaropicrin induced oxidative stress in Hep3B cells contributes to paraptotic events including endoplasmic reticulum stress and mitochondrial damage.

Purpose: Common bile duct (CBD) stone recurrence after laparoscopic CBD exploration (LCBDE) is relatively common. No studies have been conducted evaluating the safety and feasibility of re-do LCBDE in the treatment of recurrent CBD stones. Methods: This single-center retrospective study reviewed 340 consecutive patients who underwent LCBDE for CBD stones between January 2004 and December 2020. Patients with pancreatobiliary malignancies and those who underwent other surgical procedures were excluded. Results: Of the 340 included patients, 45 experienced a recurrence after a mean follow-up period of 24.2 months. Of them, 18 underwent re-do LCBDE, 20 underwent endoscopic intervention, 2 underwent radiologic intervention, and 5 underwent observation. Re-do LCBDE and initial LCBDE showed similar surgical outcomes in terms of operative time (113.1 minutes vs. 107.5 minutes, P = 0.515), estimated blood loss (42.5 mL vs. 49.1 mL, P = 0.661), open conversion rate (2.9% vs. 0%, P = 0.461), postoperative complication (15.3% vs. 22.2%, P = 0.430), and postoperative hospital stay (6.5 days vs. 6.4 days, P = 0.921). Comparing re-do LCBDE and nonsurgical treatment (endoscopic or radiologic), no statistically significant differences were noted in posttreatment complication (22.2% vs. 13.6%, P = 0.477), hospital stay (6.4 days vs.7.3 days, P = 0.607), and recurrence (50.0% vs. 36.4%, P = 0.385). The clearance rate was higher in the re-do LCBDE group than in the nonsurgical group (100% vs. 81.8%, P = 0.057). Conclusion Compared to initial LCBDE and endoscopic or radiological treatments, re-do LCBDE for recurrent CBD stones is a treatment option worth considering in selected patients.

Background: Previous studies have shown various positive associations between the usual source of care (USC) and medication adherence in chronic diseases. However, no studies specifically on patients with diabetes have been conducted in Korea. This study examined the association between the USC type and medication adherence in patients with diabetes. Methods: Data from the 2021 Korea Health Panel Survey were used. The final sample comprised 1,493 participants aged ≥20 years. The types of USC were categorized into three groups: no USC, place only (without a regular doctor [RD]), and RD. Medication adherence was assessed using detailed items (dose, frequency, time, and discontinuation) and a four-point Likert scale. Logistic regression analysis was conducted with adjustment for control variables. Results: The odds ratios (ORs) for overall medication adherence were significantly higher in the RD group at 1.66 (95% confidence interval [CI], 1.15– 2.40) than in the no-USC group. No significant difference was observed in the place-only group at 0.73 (95% CI, 0.49–1.09). The ORs for medication adherence for each item (dosage, frequency, and timing) were also significantly higher in the RD group (2.21, 1.95, and 1.67, respectively). No statistically significant differences in these parameters were observed in the place-only group. Conclusion The presence of an RD positively affected medication adherence in patients with diabetes, but the presence of place-only did not. These findings emphasize the importance of an RD for medication adherence.

Purpose: Common bile duct (CBD) stone recurrence after laparoscopic CBD exploration (LCBDE) is relatively common. No studies have been conducted evaluating the safety and feasibility of re-do LCBDE in the treatment of recurrent CBD stones. Methods: This single-center retrospective study reviewed 340 consecutive patients who underwent LCBDE for CBD stones between January 2004 and December 2020. Patients with pancreatobiliary malignancies and those who underwent other surgical procedures were excluded. Results: Of the 340 included patients, 45 experienced a recurrence after a mean follow-up period of 24.2 months. Of them, 18 underwent re-do LCBDE, 20 underwent endoscopic intervention, 2 underwent radiologic intervention, and 5 underwent observation. Re-do LCBDE and initial LCBDE showed similar surgical outcomes in terms of operative time (113.1 minutes vs. 107.5 minutes, P = 0.515), estimated blood loss (42.5 mL vs. 49.1 mL, P = 0.661), open conversion rate (2.9% vs. 0%, P = 0.461), postoperative complication (15.3% vs. 22.2%, P = 0.430), and postoperative hospital stay (6.5 days vs. 6.4 days, P = 0.921). Comparing re-do LCBDE and nonsurgical treatment (endoscopic or radiologic), no statistically significant differences were noted in posttreatment complication (22.2% vs. 13.6%, P = 0.477), hospital stay (6.4 days vs.7.3 days, P = 0.607), and recurrence (50.0% vs. 36.4%, P = 0.385). The clearance rate was higher in the re-do LCBDE group than in the nonsurgical group (100% vs. 81.8%, P = 0.057). Conclusion Compared to initial LCBDE and endoscopic or radiological treatments, re-do LCBDE for recurrent CBD stones is a treatment option worth considering in selected patients.